3386 related items for PubMed ID: 17313557
21. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F.
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[Abstract] [Full Text] [Related]
22. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP.
Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378
[Abstract] [Full Text] [Related]
23. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[Abstract] [Full Text] [Related]
24. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH.
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[Abstract] [Full Text] [Related]
25. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Davidson KL, Devaney MB, Tighe JE, Rogers SY, Dunlop DJ, Mackie MJ, Thomas RV, Johnson PR, Scotland and Newcastle Lymphoma Group Study.
Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989
[Abstract] [Full Text] [Related]
26. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[Abstract] [Full Text] [Related]
27. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[Abstract] [Full Text] [Related]
28. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Torjman L, Ladeb S, Lakhal A, Ben Othman T, Abdelkefi A, Ben Abdeladhim A.
Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
[Abstract] [Full Text] [Related]
29. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
[Abstract] [Full Text] [Related]
30. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N.
Bone Marrow Transplant; 2000 Nov 01; 26(9):971-7. PubMed ID: 11100276
[Abstract] [Full Text] [Related]
31. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A.
Ann Hematol; 2005 Aug 01; 84(8):517-25. PubMed ID: 15759115
[Abstract] [Full Text] [Related]
32. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M, Al-Kgodary T.
Bone Marrow Transplant; 2006 Apr 01; 37(8):739-43. PubMed ID: 16501587
[Abstract] [Full Text] [Related]
33. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
Bone Marrow Transplant; 1998 May 01; 21(9):873-8. PubMed ID: 9613778
[Abstract] [Full Text] [Related]
34. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P, Marolleau JP, Dombret H, Lepage E, Baruchel A, Adam M, Miclea JM, Sitthy X, Gisselbrecht C.
Bone Marrow Transplant; 1992 May 01; 9(5):337-42. PubMed ID: 1352162
[Abstract] [Full Text] [Related]
35. Intensive therapy and autotransplantation in Hodgkin's disease.
Reece DE, Phillips GL.
Stem Cells; 1994 Sep 01; 12(5):477-93. PubMed ID: 7804123
[Abstract] [Full Text] [Related]
36. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S, Dührsen U, Nückel H.
Ann Hematol; 2007 Apr 01; 86(4):271-6. PubMed ID: 17216473
[Abstract] [Full Text] [Related]
37. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
Bone Marrow Transplant; 1995 Apr 01; 15(4):549-55. PubMed ID: 7655380
[Abstract] [Full Text] [Related]
38. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK, Wittekind C, Niederwieser D.
Dtsch Med Wochenschr; 2007 Aug 01; 132(33):1688-91. PubMed ID: 17713864
[Abstract] [Full Text] [Related]
39. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y, Huang ZY, Luo LH, Yu HF.
Ai Zheng; 2008 Nov 01; 27(11):1222-5. PubMed ID: 19000458
[Abstract] [Full Text] [Related]
40. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
